Coppell, TX – According to filings with the U.S. Securities and Exchange Commission, Neurolens is raising $67,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Pierre Bertrand played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Neurolens
Modern lifestyles and persistent near vision utilization cause a majority of patients to experience the reduced visual acuity and painful symptoms of eye misalignment headaches, eye strain, neck and shoulder pain, motion sickness and dry eye sensation. Neurolens addresses common binocular vision issues using a three-step process. Step one is efficiently identifying patient symptomology using a basic online symptom screener that every patient can complete in minutes. This information goes directly to the Neurolens Measurement Device, Gen 2 or NMD2 ready for step two, which is accurately and objectively measuring the patients level of misalignment. The NMD2 is an objective, accurate and repeatable way to measure eye misalignment as small as 0. 01 Prism Diopters. Most importantly, step three is correcting eye misalignment with a proven lens solution. Neurolenses address binocular vision issues by providing a contoured prism lens design that gradually delivers more prism in the lens corridor from distance to near. Neurolenses are proven to have a profound impact on a patients visual clarity and comfort. In fact, 93% of patients responded positively to wearing Neurolenses. Over 81% of patients suffering from chronic daily headaches reported their symptoms were substantially reduced or basically gone after wearing Neurolenses for 90 days. Neurolens recognized in 2022 as one of the 30 fastest growing private companies in the healthcare industry by Inc. Magazine is confident that appropriately addressing growing binocular vision issues will become a standard of care in this industry, unlocking dramatic patient outcomes and practice growth.

To learn more about Neurolens, visit http://www.neurolens.com/

Contact:
Pierre Bertrand, Chief Executive Officer
888-236-2219
https://www.linkedin.com/in/pierresbertrand/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved